Novo Nordisk launches Wegovy weight-loss pill in US, triggering price warNovo Nordisk launches Wegovy weight-loss pill in US, triggering price war
First and only GLP-1 pill on the market costs significantly less than injectable versions The first pill version of the blockbuster GLP-1 weight loss drugs has been launched in the US by Novo Nordisk at a lower cost than jab varieties, accelerating a price war in the sector. The Danish pharmaceutical company said on Monday Read More
Hot flash drug shows added anti-cancer effect in breast cancer treatmentHot flash drug shows added anti-cancer effect in breast cancer treatment
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-estrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Oral SERD Combined With T-DXd Being Tested in HER2-Low Metastatic Breast CancerOral SERD Combined With T-DXd Being Tested in HER2-Low Metastatic Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first-in-human study evaluating the combination of the oral selective estrogen receptor degrader (SERD) elacestrant…
Novo Nordisk debuts Wegovy weight-loss pill in the U.S.Novo Nordisk debuts Wegovy weight-loss pill in the U.S.
FDA-approved semaglutide drug is the first GLP-1 pill for weight loss available in the U.S., according to drugmaker Novo Nordisk. FDA-approved semaglutide drug is the first GLP-1 pill for weight loss available in the U.S., according to drugmaker Novo Nordisk.
STAT+: Pharmalittle: We’re reading about the U.S. launch of a Wegovy pill, a Chinese biotech incubator, and moreSTAT+: Pharmalittle: We’re reading about the U.S. launch of a Wegovy pill, a Chinese biotech incubator, and more
Good morning, everyone, and welcome to another working week. We have returned from an extended break, which perhaps many of you enjoyed as well. In any event, we hope that any down time was relaxing and invigorating, because now that the calendar has turned another significant page, that predictable crunch of deadlines, online calls, and Read More
GLP-1 drugs might help quell sleep apnea, study suggestsGLP-1 drugs might help quell sleep apnea, study suggests
A good night’s sleep might be an additional benefit some gain from taking weight-loss drugs like Ozempic and Zepbound, a new study says. A good night’s sleep might be an additional benefit some gain from taking weight-loss drugs like Ozempic and Zepbound, a new study says.
Fatigue before cancer treatment linked to adverse eventsFatigue before cancer treatment linked to adverse events
Fred Hutchinson Cancer Center-led investigators found that higher patient-reported fatigue before cancer treatment aligned with higher odds of severe, life-threatening, and fatal treatment-related toxic effects.
Top Health Trends of 2026: GLP-1 Expansion, AI Wearables, MoreTop Health Trends of 2026: GLP-1 Expansion, AI Wearables, More
Which health trends will be making the biggest waves in 2026? Gretel Schueller, managing editor of health at U.S. News and World Report, joins TODAY to share an exclusive look at their list of the top emerging health trends, including an expansion of GLP-1s for more health conditions, the integration of AI into wearable technology Read More
Pill Version of Wegovy Now Available: Prices, Effectiveness, MorePill Version of Wegovy Now Available: Prices, Effectiveness, More
Novo Nordisk is announcing that a new pill version of Wegovy is now available in pharmacies across the United States. NBC’s medical contributor Dr. Natalie Azar joins TODAY to break down the available doses, its effectiveness compared to injectables, prices with and without insurance, and more. Novo Nordisk is announcing that a new pill version Read More
Semaglutide may lower burden of hospitalizations in high-risk patientsSemaglutide may lower burden of hospitalizations in high-risk patients
For patients at high cardiovascular risk with overweight or obesity, semaglutide is associated with reduced burden of total hospital admissions, according to a study published online in JAMA Cardiology. For patients at high cardiovascular risk with overweight or obesity, semaglutide is associated with reduced burden of total hospital admissions, according to a study published online Read More